No Data
No Data
Gain Therapeutics Presents Preclinical Data on GT-02287
Express News | Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics to Participate at Upcoming Investor Conferences
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $10
Express News | Gain Therapeutics Shares Are Trading Lower. The Company Announced the Presentation of a Late-breaking Abstract at the International Congress of Parkinson's Disease and Movement Disorders
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers